167 related articles for article (PubMed ID: 32437779)
1. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam.
Barnette DA; Schleiff MA; Osborn LR; Flynn N; Matlock M; Swamidass SJ; Miller GP
Toxicology; 2020 Jul; 440():152478. PubMed ID: 32437779
[TBL] [Abstract][Full Text] [Related]
2. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam.
Barnette DA; Schleiff MA; Datta A; Flynn N; Swamidass SJ; Miller GP
Toxicol Lett; 2021 Mar; 338():10-20. PubMed ID: 33253783
[TBL] [Abstract][Full Text] [Related]
3. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam.
Obach RS; Kalgutkar AS; Ryder TF; Walker GS
Chem Res Toxicol; 2008 Sep; 21(9):1890-9. PubMed ID: 18707140
[TBL] [Abstract][Full Text] [Related]
4. Importance of substituents in ring opening: a DFT study on a model reaction of thiazole to thioamide.
Bai X; Qin D; Yang L
J Mol Model; 2021 Feb; 27(3):89. PubMed ID: 33611758
[TBL] [Abstract][Full Text] [Related]
5. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Obach RS; Kalgutkar AS; Soglia JR; Zhao SX
Chem Res Toxicol; 2008 Sep; 21(9):1814-22. PubMed ID: 18690722
[TBL] [Abstract][Full Text] [Related]
6. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro.
Ludwig E; Schmid J; Beschke K; Ebner T
J Pharmacol Exp Ther; 1999 Jul; 290(1):1-8. PubMed ID: 10381752
[TBL] [Abstract][Full Text] [Related]
7. Impacts of diphenylamine NSAID halogenation on bioactivation risks.
Schleiff MA; Payakachat S; Schleiff BM; Swamidass SJ; Boysen G; Miller GP
Toxicology; 2021 Jun; 458():152832. PubMed ID: 34107285
[TBL] [Abstract][Full Text] [Related]
8. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.
Kalgutkar AS; Driscoll J; Zhao SX; Walker GS; Shepard RM; Soglia JR; Atherton J; Yu L; Mutlib AE; Munchhof MJ; Reiter LA; Jones CS; Doty JL; Trevena KA; Shaffer CL; Ripp SL
Chem Res Toxicol; 2007 Dec; 20(12):1954-65. PubMed ID: 17935300
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4.
Chesné C; Guyomard C; Guillouzo A; Schmid J; Ludwig E; Sauter T
Xenobiotica; 1998 Jan; 28(1):1-13. PubMed ID: 9493314
[TBL] [Abstract][Full Text] [Related]
10. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
11. In vitro hepatic microsomal metabolism of meloxicam in koalas (Phascolarctos cinereus), brushtail possums (Trichosurus vulpecula), ringtail possums (Pseudocheirus peregrinus), rats (Rattus norvegicus) and dogs (Canis lupus familiaris).
Kimble B; Li KM; Valtchev P; Higgins DP; Krockenberger MB; Govendir M
Comp Biochem Physiol C Toxicol Pharmacol; 2014 Apr; 161():7-14. PubMed ID: 24345479
[TBL] [Abstract][Full Text] [Related]
12. Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor.
Kalgutkar AS; Ryder TF; Walker GS; Orr ST; Cabral S; Goosen TC; Lapham K; Eng H
Drug Metab Dispos; 2013 Jul; 41(7):1375-88. PubMed ID: 23610086
[TBL] [Abstract][Full Text] [Related]
13. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics.
Schleiff MA; Flynn NR; Payakachat S; Schleiff BM; Pinson AO; Province DW; Swamidass SJ; Boysen G; Miller GP
Drug Metab Dispos; 2021 Feb; 49(2):133-141. PubMed ID: 33239334
[TBL] [Abstract][Full Text] [Related]
14. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation.
Dang NL; Hughes TB; Miller GP; Swamidass SJ
Chem Res Toxicol; 2018 Feb; 31(2):68-80. PubMed ID: 29355304
[TBL] [Abstract][Full Text] [Related]
15. Studies on microbial transformation of meloxicam by fungi.
G SP; Girisham S; Reddy SM
J Microbiol Biotechnol; 2009 Sep; 19(9):922-31. PubMed ID: 19809249
[TBL] [Abstract][Full Text] [Related]
16. In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity.
Born SL; Caudill D; Smith BJ; Lehman-McKeeman LD
Toxicol Sci; 2000 Nov; 58(1):23-31. PubMed ID: 11053537
[TBL] [Abstract][Full Text] [Related]
17. Meloxicam: metabolic profile and biotransformation products in the rat.
Schmid J; Busch U; Trummlitz G; Prox A; Kaschke S; Wachsmuth H
Xenobiotica; 1995 Nov; 25(11):1219-36. PubMed ID: 8592871
[TBL] [Abstract][Full Text] [Related]
18. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar AS; Nguyen HT
Drug Metab Dispos; 2004 Sep; 32(9):943-52. PubMed ID: 15319335
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.
Kalgutkar AS; Henne KR; Lame ME; Vaz AD; Collin C; Soglia JR; Zhao SX; Hop CE
Chem Biol Interact; 2005 Jun; 155(1-2):10-20. PubMed ID: 15978881
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
